Management of metastatic urothelial cancer: The role of surgery as an adjunct to chemotherapy

Robert S. Svatek, Arlene Siefker-Radtke, Colin P. Dinney

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations

Abstract

Metastatic or unresectable disease is identified in approximately 20% of patients presenting with invasive urothelial cancer. In addition, up to 50% of patients will develop metastases following radical cystectomy for clinically localized disease. Multiagent cisplatin-based chemotherapy is considered standard first-line treatment for these patients. Although urothelial cancer is considered a chemosensitive tumour, metastatic disease is associated with poor prognosis and short-term survival. Here, we review the role of a multidisciplinary approach to treating patients with metastatic urothelial cancer.

Original languageEnglish (US)
Pages (from-to)S228-S231
JournalJournal of the Canadian Urological Association
Volume3
Issue number6 SUPPL. 4
StatePublished - Jan 1 2009
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint

Dive into the research topics of 'Management of metastatic urothelial cancer: The role of surgery as an adjunct to chemotherapy'. Together they form a unique fingerprint.

Cite this